2014
DOI: 10.12659/msm.890671
|View full text |Cite
|
Sign up to set email alerts
|

Combination of bevacizumab and bromfenac therapy in age-related macular degeneration: A pilot study

Abstract: BackgroundAccording to recent studies, the newest strategy for the treatment of exudative age-related macular degeneration is to combine anti-VEGF agents with non-steroid anti-inflammatory drugs (NSAIDs) such as nepafenac and bromfenac to decrease the frequency of intravitreal injections. Since most research has focused on ranibizumab, the aim of this study is to evaluate whether an alternative drug such as bevacizumab could lead to similar outcomes.Material/MethodsThe study was conducted on a group of 26 pati… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2

Citation Types

0
2
0

Year Published

2015
2015
2024
2024

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 8 publications
(2 citation statements)
references
References 20 publications
0
2
0
Order By: Relevance
“…The role and effectiveness of NSAIDs combined with anti-VEGF therapy has been reported by many clinicians [ 27 30 ]. In most studies fewer injections of anti-VEGF agent in the group treated in combination with NSAIDs were recorded [ 27 ]. This usually resulted in better quality of life and economic benefits.…”
Section: Discussionmentioning
confidence: 99%
“…The role and effectiveness of NSAIDs combined with anti-VEGF therapy has been reported by many clinicians [ 27 30 ]. In most studies fewer injections of anti-VEGF agent in the group treated in combination with NSAIDs were recorded [ 27 ]. This usually resulted in better quality of life and economic benefits.…”
Section: Discussionmentioning
confidence: 99%
“…Bromfenac are nowadays being taken under consideration by many scientists [25,26,27]. The authors have recently presented the results of the above combination therapy in a pilot-study published in another journal [28].…”
Section: Discussionmentioning
confidence: 99%